Cargando…

Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019

Introduction: To realize the global goals of eliminating hepatitis B virus (HBV) and hepatitis C virus (HCV) by 2030, it is necessary to monitor the status of disease among target populations and undertake the required interventions. This study is the third round of surveys to determine the prevalen...

Descripción completa

Detalles Bibliográficos
Autores principales: Moradi, Ghobad, Alavian, Seyed Moayed, Gholami, Fatemeh, Ramezani, Rashid, Ahangarzadeh, Leila, Moradi, Yousef, Sharafi, Heidar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619467/
https://www.ncbi.nlm.nih.gov/pubmed/34832678
http://dx.doi.org/10.3390/pathogens10111522
_version_ 1784604999362281472
author Moradi, Ghobad
Alavian, Seyed Moayed
Gholami, Fatemeh
Ramezani, Rashid
Ahangarzadeh, Leila
Moradi, Yousef
Sharafi, Heidar
author_facet Moradi, Ghobad
Alavian, Seyed Moayed
Gholami, Fatemeh
Ramezani, Rashid
Ahangarzadeh, Leila
Moradi, Yousef
Sharafi, Heidar
author_sort Moradi, Ghobad
collection PubMed
description Introduction: To realize the global goals of eliminating hepatitis B virus (HBV) and hepatitis C virus (HCV) by 2030, it is necessary to monitor the status of disease among target populations and undertake the required interventions. This study is the third round of surveys to determine the prevalence of hepatitis B and C infections among incarcerated individuals in different provinces of Iran. Methods: This study was conducted in five provinces of Iran (including Kurdistan, Ardabil, West Azerbaijan, Markazi, and Semnan) in 2019. The subjects of the study were selected from incarcerated people in prisons of all provinces that had not been studied in the previous two rounds of the surveys (in 2015 and 2016) in Iran. In this study, 15 prisons were selected and 2475 incarcerated individuals were enrolled into the study based on the multistage sampling method; the selected subjects were surveyed and their dried blood spot (DBS) samples were collected to test HBsAg and HCV-Ab. In cases with a reactive result for HCV-Ab, an HCV-RNA test was also performed on their serum samples. The relationships between independent variables and outcomes were evaluated via logistic regression. Results: Of all participants (2475 subjects) enrolled in the study, 54.18% were selected from northern provinces and 45.82% from the central provinces. The prevalence of HCV-Ab and HBsAg among incarcerated individuals was 5.66% (95% CI: 4.81% to 6.64%) and 2.42% (95% CI: 1.89% to 3.11%), respectively. Among HCV-seropositive individuals, 73.68% (95% CI: 64.70% to 81.01%) had current HCV infection (detectable HCV-RNA). The results showed that histories of imprisonment, drug use, unprotected sexual contact, drug injection, tattooing, and younger age in the first-time drug use in incarcerated individuals significantly increased the risk of HCV transmission. Among these behaviors, drug injection was more likely than other behaviors to result in contracting HCV in incarcerated individuals (OR: 22.91; 95% CI: 14.92–35.18; p < 0.001). Conclusion: To achieve international and national strategies targeted to eliminate HCV and HBV by 2030, it is necessary to pay special attention to prisons in Iran. It is recommended to continue HBV vaccination of eligible people in prisons. Developing screening and treatment protocols for individuals with HCV infection in prisons can help the country to achieve HCV elimination goals.
format Online
Article
Text
id pubmed-8619467
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86194672021-11-27 Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019 Moradi, Ghobad Alavian, Seyed Moayed Gholami, Fatemeh Ramezani, Rashid Ahangarzadeh, Leila Moradi, Yousef Sharafi, Heidar Pathogens Article Introduction: To realize the global goals of eliminating hepatitis B virus (HBV) and hepatitis C virus (HCV) by 2030, it is necessary to monitor the status of disease among target populations and undertake the required interventions. This study is the third round of surveys to determine the prevalence of hepatitis B and C infections among incarcerated individuals in different provinces of Iran. Methods: This study was conducted in five provinces of Iran (including Kurdistan, Ardabil, West Azerbaijan, Markazi, and Semnan) in 2019. The subjects of the study were selected from incarcerated people in prisons of all provinces that had not been studied in the previous two rounds of the surveys (in 2015 and 2016) in Iran. In this study, 15 prisons were selected and 2475 incarcerated individuals were enrolled into the study based on the multistage sampling method; the selected subjects were surveyed and their dried blood spot (DBS) samples were collected to test HBsAg and HCV-Ab. In cases with a reactive result for HCV-Ab, an HCV-RNA test was also performed on their serum samples. The relationships between independent variables and outcomes were evaluated via logistic regression. Results: Of all participants (2475 subjects) enrolled in the study, 54.18% were selected from northern provinces and 45.82% from the central provinces. The prevalence of HCV-Ab and HBsAg among incarcerated individuals was 5.66% (95% CI: 4.81% to 6.64%) and 2.42% (95% CI: 1.89% to 3.11%), respectively. Among HCV-seropositive individuals, 73.68% (95% CI: 64.70% to 81.01%) had current HCV infection (detectable HCV-RNA). The results showed that histories of imprisonment, drug use, unprotected sexual contact, drug injection, tattooing, and younger age in the first-time drug use in incarcerated individuals significantly increased the risk of HCV transmission. Among these behaviors, drug injection was more likely than other behaviors to result in contracting HCV in incarcerated individuals (OR: 22.91; 95% CI: 14.92–35.18; p < 0.001). Conclusion: To achieve international and national strategies targeted to eliminate HCV and HBV by 2030, it is necessary to pay special attention to prisons in Iran. It is recommended to continue HBV vaccination of eligible people in prisons. Developing screening and treatment protocols for individuals with HCV infection in prisons can help the country to achieve HCV elimination goals. MDPI 2021-11-21 /pmc/articles/PMC8619467/ /pubmed/34832678 http://dx.doi.org/10.3390/pathogens10111522 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Moradi, Ghobad
Alavian, Seyed Moayed
Gholami, Fatemeh
Ramezani, Rashid
Ahangarzadeh, Leila
Moradi, Yousef
Sharafi, Heidar
Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
title Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
title_full Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
title_fullStr Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
title_full_unstemmed Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
title_short Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
title_sort prevalence of hepatitis b and hepatitis c infections among incarcerated individuals in iran: a cross-sectional national bio-behavioral study in 2019
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619467/
https://www.ncbi.nlm.nih.gov/pubmed/34832678
http://dx.doi.org/10.3390/pathogens10111522
work_keys_str_mv AT moradighobad prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019
AT alavianseyedmoayed prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019
AT gholamifatemeh prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019
AT ramezanirashid prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019
AT ahangarzadehleila prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019
AT moradiyousef prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019
AT sharafiheidar prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019